Powdered Milk Product with Angiogenin and Lactoperoxidase for Bone Density
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating bone diseases such as osteoporosis, fracture, and arthritis are limited by low calcium absorption rates and side effects associated with existing drugs, making it difficult to develop safe and effective oral food or drink products that can promote bone formation and suppress bone resorption.
Innovation Solution
A powdered milk product containing angiogenin and/or angiogenin hydrolysate in combination with lactoperoxidase and/or lactoperoxidase hydrolysate in specific mass ratios, administered orally to enhance bone density and strength.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If calcium salt or natural calcium product is administered to strengthen bones, then calcium intake is increased, but calcium absorption rate is 50% or less and most calcium is discharged without being absorbed
Solution Approach 1:
The patent introduces casein phosphopeptide as an intermediary substance that mediates between calcium and the intestinal absorption system. Casein phosphopeptide binds to calcium to form a complex that is readily absorbed by the intestine, thereby improving calcium absorption efficiency from 50% or less to significantly higher rates while maintaining safe calcium intake levels.
Solution Approach 2:
The patent changes the chemical form of calcium from simple calcium salts to calcium-casein phosphopeptide complexes. This parameter change in calcium's molecular structure and binding state fundamentally alters its absorption characteristics, enabling more efficient intestinal uptake and reducing calcium loss through discharge.
2Strength
If existing bone-strengthening drugs are administered to treat osteoporosis, then bone strength is improved, but side effects such as buzzing in the ear, headache, or loss of appetite occur
Solution Approach 1:
The patent replaces long-term use of pharmaceutical interventions with a food-based approach using casein phosphopeptide and calcium. This substitutive strategy achieves bone-strengthening effects through nutritional means rather than pharmacological ones, eliminating the need for continuous drug administration and its associated side effects while maintaining therapeutic benefits.
Solution Approach 2:
The patent uses casein phosphopeptide as a natural intermediary that facilitates calcium absorption and bone formation through physiological pathways rather than pharmacological intervention. This intermediary approach leverages the body's natural metabolic processes to achieve bone strengthening without introducing foreign pharmaceutical agents that cause side effects.
3Quantity of substance
If calcium is absorbed into the body, then calcium availability increases, but it does not necessarily exhibit bone metabolism-improving effect or bone-strengthening effect since affinity to bones may differ according to its form
Solution Approach 1:
The patent changes calcium's binding parameters by forming complexes with casein phosphopeptide, which has specific amino acid sequences that enhance calcium's affinity for bone tissue. This parameter change in calcium's chemical environment fundamentally alters its biological behavior, directing absorbed calcium preferentially to bone sites and ensuring it exhibits bone metabolism-improving effects rather than being distributed systemically without targeted benefit.
Data Source
AI summary
The invention relates to a powdered milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 1.4 to 24 mg/15 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.35 to 10.